Bausch + Lomb Corporation (BLCO)
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.07 per share a year ago.
Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript
Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position
Caspian Capital increased its Bausch + Lomb Corporation stake by 1,349,043 shares in the fourth quarter; the estimated trade value was $21.39 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $21.61 million, reflecting both trading and price changes.
Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should Know
Bausch + Lomb (BLCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript
Bausch + Lomb (BLCO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch + Lomb (BLCO) Lags Q4 Earnings Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.25 per share a year ago.
Ahead of Bausch + Lomb (BLCO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Bausch + Lomb (BLCO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
BLCO or DHR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
BLCO vs. HQY: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Bausch + Lomb (BLCO) or HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript
